{"name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","slug":"immuneonco-biopharmaceuticals-shanghai-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"IMC-001 and Optimal medical treatment","genericName":"IMC-001 and Optimal medical treatment","slug":"imc-001-and-optimal-medical-treatment","indication":"Other","status":"phase_2"},{"name":"IMM01","genericName":"IMM01","slug":"imm01","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"IMC-001 and Optimal medical treatment","genericName":"IMC-001 and Optimal medical treatment","slug":"imc-001-and-optimal-medical-treatment","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMM01","genericName":"IMM01","slug":"imm01","phase":"phase_3","mechanism":"IMM01 is an immunotherapeutic agent designed to enhance anti-tumor immune responses, likely through modulation of immune checkpoint pathways or T-cell activation.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQc0E0M18xMXVnOHI0bXVfb05OYnZMN3B2RjlwWHBUdjFlNWJXbWNjSjNNMjFyMnhrNlBnbkFFcTFDR3Z5MlIwZ0ZZXzE0bk9haWNSX09iNzhLRW0zdzlDTDJjRTFHSWlub01nUVI5ZmtJSFdzcTRWT0lsRUcyQV9IMWZqbWxBRG1kWGlBaHJFajZMeC1CRTBfLUxiWFhOYnJDUHVFNTM2UURaOVM2U0ZsMFB2MkpHR0tuZlZ2ejc5S2tMU3A1NGcxUHBLdw?oc=5","date":"2026-01-14","type":"deal","source":"Caixin Global","summary":"Chinese Drugmakers Strike Record $136 Billion in Cross-Border Licensing Deals - Caixin Global","headline":"Chinese Drugmakers Strike Record $136 Billion in Cross-Border Licensing Deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOU3A0UVRucE1wOXF6cUVSMEI3ejdBVDRWZmRkVUJKaWt1WnlWaDQwaWkydS0yRzdCdGFGaTY3d2I1UHJCUDN3WWJncFR1MEdQMDBOOGRyYm4teWJta1BRSXB1QUotVFBNaE9NV2UxaHVsSnU2TXpOU3drWmJlR0dPWXBQcFF5U1pZYmZyMjF2V3h2MFZrUWM1NVJpQzB3cjB5WUJsN1NEbzEzRnh2RGF6dFZGc1JvYnRuU1E?oc=5","date":"2026-01-06","type":"pipeline","source":"Stock Titan","summary":"Instil Bio and ImmuneOnco unwind AXN-2510 pact as development stops - Stock Titan","headline":"Instil Bio and ImmuneOnco unwind AXN-2510 pact as development stops","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPdmttS3RaMjJLR1JvQjFoMlBQRDFMMXZ3U1FLU0RCNldkRUtKWkFPaWVNREFIdVpmWjJMOG9VZi1mejNTWHRJZURTNElOTU1jVUprdVBNdHFOZkRMTjItNGRkZGVsaVh3X0tHekktMWNjLXl1LWFXSmhtNWt2UEp2VlNWTDVmenFDbGpnYXRHOGhjVmROX3UtSlNQXzg1bzlpOGRhbk9LYnY2bHRHZjAzcE5DZXpDYkE4MG40akJSMUV0MnAw?oc=5","date":"2025-09-30","type":"pipeline","source":"Markets Mojo","summary":"Hang Seng Index Soars 1.89% as Huatai Securities Leads with 12.55% Gain! - Markets Mojo","headline":"Hang Seng Index Soars 1.89% as Huatai Securities Leads with 12.55% Gain!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wVEVWOEFSaXpIWmJGTXJaREVfYWw3X055bFYzYk52azZ5S0o4Tlh2V3pYRjJOQWdMR05uMjR4b2FGU0liakFXWjZIYVZrQlF2N0FtRGd3?oc=5","date":"2025-07-24","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Nanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Nanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOUFN3UzNaTU5xT0tjNXlKVDExaEM4emFJS1VvUjUxZEVaVFhlMEpYa3czOUJHQm5jaE42aFNkTFFrMmN4WWp4VFU0WEMzdDJnR3dpWktBZjFta19kVzMtazRoOGFmUWtrM3BYaEpaQUJwZGhad2o0cHJVZ2kydm90ekQ1Z0hyUQ?oc=5","date":"2024-10-15","type":"deal","source":"BioXconomy","summary":"Asia biopharma deals: August 2024 - BioXconomy","headline":"Asia biopharma deals: August 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQX2NiX2psenFNV0dqc2I4dDB2NjZTN05XTHZ5VF9hMGwtVU50dk5lOUwtZFA1SW5BaEd0UDhjeEcwSDBfV2Fuc1htUTNiRUltdWdHWC10VjBiWXlMMlJHcFhhdXpHZXNyX1RvRkJsVndhR25jSXhWaEdJdEM3akpfYXNsVlhDeXlqR0c2dndTQkpmMWlxb2FZc1k0OUhMby04UkpKRGkzME00LW0yd01tQTY4SjQ?oc=5","date":"2022-07-05","type":"deal","source":"BioWorld News","summary":"Sunshine Guojian grants Xiling Lab global ADC project rights in ¥1.03B deal - BioWorld News","headline":"Sunshine Guojian grants Xiling Lab global ADC project rights in ¥1.03B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPb0hoc05sM2Y2bDJEYXZyMktyU0VScHpabVB3cnpyZjEzc2dPUzJyYXF4cjg1aXJHLXBIQjFJcV84bU55YTlEY2Z4czJWeENWemIzc3ZHM0xYNmZZOVJxVHNnZi1VUnU2QXlWX3hySTQxMllnWDhDb21PejQ1d0FKNndOZDhJRGZQMW9xNzJHLUFRTHF0bUtfbWx3?oc=5","date":"2017-11-05","type":"pipeline","source":"hkex.com.hk","summary":"China Dimension - hkex.com.hk","headline":"China Dimension","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}